Intuitive Surgical vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Robotic surgery pioneer with 9,800+ da Vinci systems; da Vinci 5 adds haptic feedback; $8.35B FY2024 revenue; 57,000+ trained surgeons create switching costs; J&J and Medtronic competing.
About
Intuitive Surgical is the global pioneer and dominant leader in robotic-assisted minimally invasive surgery, founded in 1995 and headquartered in Sunnyvale, California. The company trades on Nasdaq (ISRG) and reported $8.35 billion in FY2024 revenue, representing approximately 17% year-over-year growth, with an installed base of nearly 9,800 da Vinci surgical systems deployed in hospitals across 70+ countries. The fourth-generation da Vinci 5 system—launched in 2024—introduced haptic force feedback for the first time, allowing surgeons to sense tissue resistance through robotic instruments, a breakthrough that strengthens Intuitive's technical moat and accelerates system upgrades among existing customers.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.